2nd SOHO Italian Conference

http://www.sohoitaly.it/

 

2nd SOHO Italian Conference
Avatar

2020 SOHO Update on Immunotherapy in AML: Gemtuzumab Ozogamicin Plus 7+3 vs. 7+3, CD123-Targeting ADC IMGN632 & Azacitidine + Nivolumab in R/R AML, Anti-CD47 Antibody Magrolimab + Azacitidine

By 2nd SOHO Italian Conference FEATURING Naval Daver
By 2nd SOHO Italian Conference FEATURING Naval Daver
122 views
December 7, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Leukemia
14:51

MRD & ALL Management: What Role Does It Play in AlloHSCT Setting?

2nd SOHO Italian Conference

A. Rambaldi

26 views
17:00

How I Treat AML at MD Anderson: ATRA & GO Combos, Sequential HD Chem…

2nd SOHO Italian Conference

H. Kantarjian

195 views
09:43

MD Anderson Future Directions in AML: Efficacy of FLT3 / IDH Inhibit…

2nd SOHO Italian Conference

H. Kantarjian

303 views
10:02

How I Treat ALL at MD Anderson: What Hyper-CVAD Combinations Showed …

2nd SOHO Italian Conference

H. Kantarjian

30 views
13:11

MD Anderson Future Directions in ALL: How Effective Are New Blina/In…

2nd SOHO Italian Conference

H. Kantarjian

17 views
13:38

TFR and CML: Why Is TFR Important? What Happens After? Why Is It Dif…

2nd SOHO Italian Conference

E. Abruzzese

11 views
08:52

TFR in CML: What Are the Influencing Factors? Do Patients Lose MR Af…

2nd SOHO Italian Conference

M. Malagola

12 views
14:09

How I Treat Frontline CML: What Are the Differences in ELTS vs. Soka…

2nd SOHO Italian Conference

G. Saglio

16 views
09:15

Post-SCT Maintenance in AML: What Is the Role of Hypomethylating Age…

2nd SOHO Italian Conference

A. Sperotto

21 views
15:37

Allogenic Transplant in AML: How Does ASCT Compare to Chemo in Older…

2nd SOHO Italian Conference

A. Olivieri

18 views
13:56

MRD Assessment in Frontline AML: What Are the Characteristics of Dif…

2nd SOHO Italian Conference

F. Buccisano

21 views
09:22

Prognostic Relevance of BPDCN-Like Phenotype in Newly Diagnosed AML:…

2nd SOHO Italian Conference

R. Lemoli

21 views
11:45

Pro-Apoptotic Pathways in AML: How Does Venetoclax Work in Combinati…

2nd SOHO Italian Conference

S. Galimberti

10 views
14:40

Genomic Sequencing in AML and MDS: How Can We Define Subtypes and Mu…

2nd SOHO Italian Conference

I. Iacobucci

25 views
12:17

Novel mAbs in ALL: Is Ino Better than SoC? What Is the MRD-Negativit…

2nd SOHO Italian Conference

F. Lanza

11 views
10:44

mAbs in ALL: Does Blinatumomab Prolong Survival in R/R Ph+/- Disease…

2nd SOHO Italian Conference

C. Papayannidis

11 views
08:04

Cell Morphology in Acute Leukemias & Hematologic Malignancies: Diffe…

2nd SOHO Italian Conference

G. Zini

28 views
11:05

Synthetic Lethality Against ALL: How Often Is the Expression of DDR-…

2nd SOHO Italian Conference

A. Ghelli Luserna Di Rora

13 views
14:43

2020 SOHO Update on R/R ALL: Is CD19-Targeted CAR-T Beneficial for O…

2nd SOHO Italian Conference

J. Ribera

85 views
16:49

2020 SOHO Updates on ALL: Does Ponatinib+Steroids Help Induce CHR in…

2nd SOHO Italian Conference

G. Martinelli

138 views
11:57

2020 SOHO Updates on Newly Diagnosed AML: Does CPX-351 Increase OS a…

2nd SOHO Italian Conference

C. Cerchione

97 views
10:44

2020 SOHO Updates on AML: Is Targeting CAMDR a New Frontier? Can E-S…

2nd SOHO Italian Conference

C. Cerchione

90 views
18:18

MD Anderson State of the Art in CLL Treatment: What Is Changing and …

2nd SOHO Italian Conference

A. Ferrajoli

168 views
10:10

2020 SOHO Updates on Newly Diagnosed AML: What Is the ORR With Aza v…

2nd SOHO Italian Conference

A. de la Fuente

37 views
16:49

2020 SOHO Update on Ph-Like ALL: How Important Are Genomic Alteratio…

2nd SOHO Italian Conference

M. Konopleva

17 views
19:30

2020 SOHO Update on AML in Older Patients at MD Anderson: Therapy In…

2nd SOHO Italian Conference

T. Kadia

191 views
22:54

2020 SOHO Update on MPN: Ruxolitinib vs. BAT in ET, Ruxolitinib in P…

2nd SOHO Italian Conference

S. Verstovsek

24 views
18:07

2020 SOHO Update on Diagnostic Approaches to Ph-Like B-ALL: CRLF2 De…

2nd SOHO Italian Conference

S. Konoplev

10 views
09:51

2020 SOHO Update on FLT3+ AML: What Are the Novel FLT3 Inhibitors? H…

2nd SOHO Italian Conference

N. Daver

60 views
14:15

2020 SOHO Update on Immunotherapy in AML: Gemtuzumab Ozogamicin Plus…

2nd SOHO Italian Conference

N. Daver

122 views
16:36

How I Manage CML at MD Anderson in 2020: How Effective & Safe Is Das…

2nd SOHO Italian Conference

E. Jabbour

18 views
13:05

2020 SOHO Update on Frontline Therapy Optimization in ALL: How Effec…

2nd SOHO Italian Conference

E. Jabbour

19 views
10:43

2020 SOHO Update on Frontline MDS: What Is the Role of Genomic Annot…

2nd SOHO Italian Conference

G. Garcia-Manero

13 views
12:20

2020 SOHO Update on Antibodies in AML: Is Gemtuzumab Ozogamicin Effe…

2nd SOHO Italian Conference

F. Ravandi

15 views
12:54

2020 SOHO Update on Maintenance AML: Does It Improve Clinical Outcom…

2nd SOHO Italian Conference

F. Ravandi

15 views